Cargando…
Dupilumab efficacy and safety in patients with asthma and blood eosinophils ≥500 cells·µL(−1)
Dupilumab is well tolerated and improves clinical outcomes in patients with asthma and high eosinophils (≥500 cells·µL(−1)). Improvements in clinical outcomes correlate with eosinophil counts, demonstrating dupilumab efficacy in those with high eosinophils. https://bit.ly/3Jxvicb
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
European Respiratory Society
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9218240/ https://www.ncbi.nlm.nih.gov/pubmed/35487538 http://dx.doi.org/10.1183/13993003.02577-2021 |